Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Transferon is a human dialyzable leukocyte extract (hDLE) developed by the National Polytechnic Institute (IPN) of Mexico. It is a complex biologic product composed of low-molecular-weight peptides (less than 10 kDa) obtained from the dialysis of disintegrated human leukocytes. Transferon acts as an immunomodulator by promoting the cellular immune response, specifically by inducing the production of Th1 cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), and by increasing the activity of natural killer (NK) cells and T-lymphocytes. It is used as an adjuvant therapy for various conditions involving immune dysregulation, including infectious diseases (such as herpes zoster and hepatitis), allergic disorders (like atopic dermatitis and asthma), and certain types of cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Transferon.